CORRECTION

Correction to: Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports

Paul D. Terry · Rajiv Dhand

Published online: July 24, 2021
© Springer Healthcare Ltd., part of Springer Nature 2021

Correction to: Adv Ther (2020) 37:1812–1828
<https://doi.org/10.1007/s12325-020-01289-y>

The original article can be found online at <https://doi.org/10.1007/s12325-020-01289-y>.

P. D. Terry · R. Dhand (✉)
Department of Medicine, Graduate School of
Medicine, University of Tennessee Medical Center,
Knoxville, TN, USA
e-mail: rdhand@utmck.edu; rdhand@uthsc.edu

Table 4 Drug combinations, devices and doses for treating patients with stable COPD in the GOLD reports, 2001–2020

Drug	Inhaler (µg)	Solution for nebulizer (mg/ml)	Duration of action (h)
Combination short-acting β ₂ -agonists plus anticholinergic in one inhaler			
Fenoterol/Ipratropium ^a	200/80 (pMDI)	1.25/0.5 in 4 ml	6–8
Albuterol/Ipratropium ^a	75/15 (pMDI) ^b	0.75/4.5 → 0.5, 2.5 in 3 ml ^c	6–8
	100/20 (SMI) ^d		6–8
Combination long-acting β ₂ -agonists plus anticholinergic in one inhaler			
Indacaterol/glycopyrronium ^e	85/43 (DPI)		24
Vilanterol/umeclidinium ^f	25/62.5 (DPI)		24
Formoterol/aclidinium ^g	12/340 (DPI)		12
Olodaterol/tiotropium ^h	5/5 (SMI)		24
Formoterol/glycopyrronium ⁱ	9.6/14.4 → 9.6/18 (pMDI)		12
Formoterol/glycopyrrolate ^j	4.8/9		12
Combination long-acting β ₂ -agonists plus glucocorticosteroids in one inhaler			
Formoterol/Budesonide ^k	4.5/160 (pMDI)		
	9/320 (DPI)		
Formoterol/mometasone ^l	10/200, 10/400 (pMDI)		
Salmeterol/Fluticasone ^m	50/100, 250, 500 (DPI)		
	25/50, 125, 250 (pMDI)		
Vilanterol/Fluticasone furoate ⁿ	25/100 (DPI)		
Formoterol/Beclomethasone ^o	6/100 (pMDI & DPI)		
Triple Combination in one device (LABA/LAMA/ICS) ^p			
Fluticasone/umeclidinium/vilanterol ^q (DPI)			

Table 4 continued

Drug	Inhaler (µg)	Solution for nebulizer (mg/ml)	Duration of action (h)
Beclometasone/formoterol/ glycopyrronium ^r (pMDI)			

Specific doses were no longer shown in “Commonly Used Maintenance Medications in COPD” after 2018

^a Combination added in 2003

^b pMDI formulation for Albuterol/Ipratropium combination was discontinued after 2013

^c Albuterol/Ipratropium combination solution for nebulizer was changed to 0.75/0.5 in 2010, discontinued in 2013, and added back as 0.5, 0.25 mg/ml in 2017

^d A soft mist inhaler (SMI) formulation for Albuterol/Ipratropium combination (100/20 µg) was added in 2014

^e Indacaterol/glycopyrronium combination was added in 2014

^f Vilanterol/umeclidinium combination was added in 2014

^g Formoterol/acclidinium combination was added in 2015

^h Olodaterol/tiotropium combination was added in 2017

ⁱ Formoterol/glycopyrronium combination was added in 2017; dose was changed to 9.6/18 in 2018

^j Formoterol/glycopyrrolate combination was added in 2018

^k Formoterol/Budesonide combination was added in 2003

^l Formoterol/Mometasone combination was added in 2013

^m Salmeterol/Fluticasone combination was added in 2003

ⁿ Vilanterol/Fluticasone combination was added in 2014

^o Formoterol/Beclomethasone combination was added in 2015 for pMDI; DPI formulation was added in 2016

^p Triple therapy was added to GOLD’s “Commonly Used Maintenance Medications in COPD” table in the 2019 Report

^q Fluticasone/umeclidinium/vilanterol combination was added in 2019 (doses and devices were not specified)

^r Beclometasone/formoterol/glycopyrronium combination was added in 2019 (doses and devices were not specified)

In the Original Article, Table 4 was published incorrectly. The correct Table 4 is given below.